The NCI requires that each Cancer Center maintain a Protocol Review and Monitoring System (PRMS) to assess scientific merit and feasibility of all protocols studying subjects diagnosed with, or at risk for, cancer conducted at the Center, and to monitor for accrual and scientific relevance. NCI looks for centralized oversight across the entire Center; the Protocol Review Committee (PRC) serves as the centralized portion of this requirement (as opposed to the Disease Site Committees).
The PRC is charged with review of the scientific rationale, study design, expected accrual rates, adequacy of biostatistical input, feasibility for completion within a reasonable time period, prioritization in terms of scientific merit and patient availability, and review of scientific progress including reasonable study goals and accrual rates. The PRC has final authority regarding protocol and amendment review and approval, accrual monitoring, and study closure. The UCSF IRB, the Committee on Human Research (CHR), will not grant initial approval for any cancer-related study until the PRC has granted full approval or exemption, and may hold up approval of a protocol amendment if not reviewed by the PRC prior to CHR review.
All studies reviewed by the PRC will be subject to:
Email firstname.lastname@example.org with any questions.
> for Protocol Review Committee review process policies see ITR Policies
This unit is supported by a National Cancer Institute Cancer Center Support Grant (5P30CA082103). Any publications related to work done by this core should reference grant number 5P30CA082103 and must include a PMCID as required by the NIH. For complete instructions on how to acknowledge funding sources, please see http://grants.nih.gov/grants/acknow.htm. For more information on how to obtain a PMCID, please see http://publicaccess.nih.gov/submit_process.htm.
For more information on the CCSG, please contact Erin Bank, PhD, at email@example.com.